Clinical evaluation of endoscopic biliary stenting in treatment of malignant obstructive jaundice

Table 1 Baseline characteristics of the observation and control groups

Index	Observation group (n = 29)	Control group (n = 30)	t/χ²	P value
Gender
Male	18	17	0.178	0.673
Female	11	13	/	/
Age (years), mean ± SD	52.68 ± 3.65	53.48 ± 3.62	1.205	0.230
Tumor type
Cholangiocarcinoma	6	7	0.060	0.807
Gallbladder cancer	7	8	0.050	0.823
Liver cancer	6	4	0.685	0.165
Ampullary carcinoma	3	5	0.108	0.742
Pancreatic cancer	7	6	0.098	0.754
Tumor diameter
< 3 cm	11	12	0.027	0.871
≥ 3 cm	18	18	/	/

Table 2 Comparison of liver function indicators between the observation and control groups, mean ± SD

Indicator	Observation group (n = 29)	Control group (n = 30)	t	P value
ALT (U/L)
Preoperative	107.66 ± 45.66	101.54 ± 42.68	0.759	0.450
Postoperative	49.66 ± 6.26a	52.81 ± 6.74a	1.859	0.068
AST (U/L)
Preoperative	129.66 ± 11.29	126.34 ± 10.75	1.650	0.102
Postoperative	74.89 ± 6.31a	78.43 ± 7.89a	1.899	0.063
TBIL (μmol/L)
Preoperative	186.58 ± 59.38	189.61 ± 60.59	0.783	0.277
Postoperative	90.65 ± 50.11a	104.64 ± 47.65a	1.099	0.276

^aP < 0.05 indicates a significant improvement compared with the preoperative values.

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin.

Table 3 Incidence of complications between the observation and control groups, n (%)

Group	Biliary tract bleeding	Gastrointestinal bleeding	Pancreatitis	Cholangitis	Total incidence
Observation group (n = 29)	1 (3.45)	0 (0.00)	0 (0.00)	1 (3.45)	2 (6.90)
Control group (n = 30)	2 (6.67)	3 (10.00)	1 (3.33)	3 (10.00)	9 (30.00)
P value	-	-	-	-	0.023
χ²	-	-	-	-	5.189

Table 4 Occurrence of adverse events within 1 month after surgery, n (%)

Group	Blood transfusion within 1 month	ICU admission	Death within 3 years
Observation group (n = 29)	16 (55.17)	17 (58.62)	11 (37.93)
Control group (n = 30)	21 (70.00)	22 (73.33)	13 (43.33)
χ²	1.386	1.425	0.178
P value	0.239	0.233	0.673

ICU: Intensive care unit.